Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pál Pacher

Showing results (1-10 of 171) with videos related to

Pageof 18
Sort By:
British Journal of Pharmacology|August 2, 2012
Towards the use of non-psychoactive cannabinoids for prostate cancerPál Pacher
Journal of Leukocyte Biology|December 28, 2007
A2A receptors in inflammation and injury: lessons learned from transgenic animalsGyörgy Haskó, Pál Pacher
American Journal of Physiology. Gastrointestinal and Liver Physiology|February 2, 2008
Endocannabinoids and liver disease. III. Endocannabinoid effects on immune cells: implications for inflammatory liver diseasesPál Pacher, Bin Gao
Seminars in Immunopathology|April 10, 2009
The emerging role of the endocannabinoid system in cardiovascular diseasePál Pacher, Sabine Steffens
The FEBS Journal|April 5, 2013
Modulating the endocannabinoid system in human health and disease--successes and failuresPál Pacher, George Kunos
Journal of Molecular Medicine (Berlin, Germany)|February 29, 2012
Interplay of cannabinoid 2 (CB2) receptors with nitric oxide synthases, oxidative and nitrative stress, and cell death during remote neurodegenerationPál Pacher, Ken Mackie
Arteriosclerosis, Thrombosis, and Vascular Biology|March 17, 2012
Regulation of macrophage function by adenosineGyörgy Haskó, Pál Pacher
British Journal of Pharmacology|May 23, 2012
Targeting cannabinoid receptor CB(2) in cardiovascular disorders: promises and controversiesSabine Steffens, Pál Pacher
Orvosi Hetilap|April 6, 2004
[Cardiovascular effects of selective serotonin reuptake inhibitor antidepressants]Pál Pacher, Valéria Kecskeméti
Pharmacological Research|July 2, 2009
Endocannabinoids and cardiac contractile function: pathophysiological implicationsSándor Bátkai, Pál Pacher
Pageof 18

Showing results (1-10 of 171) with videos related to

Sort By:
Pageof 18
British Journal of Pharmacology|August 2, 2012
Towards the use of non-psychoactive cannabinoids for prostate cancerPál Pacher
Journal of Leukocyte Biology|December 28, 2007
A2A receptors in inflammation and injury: lessons learned from transgenic animalsGyörgy Haskó, Pál Pacher
American Journal of Physiology. Gastrointestinal and Liver Physiology|February 2, 2008
Endocannabinoids and liver disease. III. Endocannabinoid effects on immune cells: implications for inflammatory liver diseasesPál Pacher, Bin Gao
Seminars in Immunopathology|April 10, 2009
The emerging role of the endocannabinoid system in cardiovascular diseasePál Pacher, Sabine Steffens
The FEBS Journal|April 5, 2013
Modulating the endocannabinoid system in human health and disease--successes and failuresPál Pacher, George Kunos
Journal of Molecular Medicine (Berlin, Germany)|February 29, 2012
Interplay of cannabinoid 2 (CB2) receptors with nitric oxide synthases, oxidative and nitrative stress, and cell death during remote neurodegenerationPál Pacher, Ken Mackie
Arteriosclerosis, Thrombosis, and Vascular Biology|March 17, 2012
Regulation of macrophage function by adenosineGyörgy Haskó, Pál Pacher
British Journal of Pharmacology|May 23, 2012
Targeting cannabinoid receptor CB(2) in cardiovascular disorders: promises and controversiesSabine Steffens, Pál Pacher
Orvosi Hetilap|April 6, 2004
[Cardiovascular effects of selective serotonin reuptake inhibitor antidepressants]Pál Pacher, Valéria Kecskeméti
Pharmacological Research|July 2, 2009
Endocannabinoids and cardiac contractile function: pathophysiological implicationsSándor Bátkai, Pál Pacher
Pageof 18